{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:28:55Z","timestamp":1791343735769,"version":"4.3.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":151,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009192","name":"Alberta Innovates","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009192","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.gastha.2024.05.010","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T15:16:41Z","timestamp":1717600601000},"page":"965-972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Projected Healthcare System Cost Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in Canada"],"prefix":"10.1016","volume":"3","author":[{"given":"K. Ally","family":"Memedovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel Aziz","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona M.","family":"Clement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gastha.2024.05.010_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/joim.13069","article-title":"Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016","volume":"288","author":"Zou","year":"2020","journal-title":"J\u00a0Intern Med"},{"issue":"11","key":"10.1016\/j.gastha.2024.05.010_bib2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gastha.2024.05.010_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jhep.2023.01.026","article-title":"Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties","volume":"79","author":"Allen","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.gastha.2024.05.010_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.gastha.2024.05.010_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147237","article-title":"Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score","volume":"11","author":"Tapper","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.gastha.2024.05.010_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gastha.2024.05.010_bib7","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/hep.30094","article-title":"Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. Claims database","volume":"68","author":"Allen","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.gastha.2024.05.010_bib8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.gastha.2024.05.010_bib9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40273-015-0316-5","article-title":"Economic and quality-of-life implications of non-alcoholic fatty liver disease","volume":"33","author":"Younossi","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.gastha.2024.05.010_bib10","doi-asserted-by":"crossref","first-page":"E429","DOI":"10.9778\/cmajo.20190212","article-title":"Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study","volume":"8","author":"Swain","year":"2020","journal-title":"CMAJ Open"},{"issue":"2","key":"10.1016\/j.gastha.2024.05.010_bib11","doi-asserted-by":"crossref","first-page":"E370","DOI":"10.9778\/cmajo.20200009","article-title":"Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study","volume":"8","author":"Shaheen","year":"2020","journal-title":"CMAJ Open"},{"issue":"1","key":"10.1016\/j.gastha.2024.05.010_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.diii.2015.11.001","article-title":"Shear wave elastography: an accurate technique to stage liver fibrosis in chronic liver diseases","volume":"97","author":"Guibal","year":"2016","journal-title":"Diagn Interv Imaging"},{"issue":"1","key":"10.1016\/j.gastha.2024.05.010_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4254\/wjh.v9.i1.38","article-title":"Ultrasound shear wave elastography and liver fibrosis: a Prospective Multicenter Study","volume":"9","author":"Sande","year":"2017","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1016\/j.gastha.2024.05.010_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3138\/canlivj-2021-0030","article-title":"Current considerations for clinical management and care of non-alcoholic fatty liver disease: insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)","volume":"5","author":"Sebastiani","year":"2022","journal-title":"Can Liver J"},{"issue":"4","key":"10.1016\/j.gastha.2024.05.010_bib20","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.gastha.2024.05.010_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.gastha.2024.05.010_bib22","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572324000785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572324000785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T02:06:29Z","timestamp":1728957989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572324000785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2772572324000785"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2024.05.010","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Projected Healthcare System Cost Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in Canada","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2024.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}